Document is current
Any future updates will be listed below
-
Authors
Chabrun, Floris https://orcid.org/0000-0001-6871-8711
Schwartz, Daniel E. https://orcid.org/0000-0002-3144-7919
Gentile, Susanna https://orcid.org/0000-0002-1274-8177
Mai, Elias K. https://orcid.org/0000-0002-6226-1252
Gupta, Tulika R.
Perry, Jacqueline
Cordas dos Santos, David M. https://orcid.org/0000-0002-9198-8338
Hielscher, Thomas
Werly, Annika
Schmidt, Sophia K.
Theodorakakou, Foteini
Fotiou, Despina
Liacos, Christine Ivy
Kanellias, Nikolaos
Gisbert, Noelia Collado
Martin-Sanchez, Esperanza
Termini, Rosalinda
Waldschmidt, Johannes https://orcid.org/0000-0001-5340-1818
Chavda, Selina J.
Ainley, Louise
Da Vià, Matteo Claudio
De Magistris, Claudio
Pettine, Loredana
Timonian, Michael A. https://orcid.org/0000-0002-1014-3502
Alberge, Jean-Baptiste https://orcid.org/0000-0002-4218-7294
Patel, Vidhi
Costello, Patrick
Tobia, Catherine
Phan, Sally
Lamb, Jennifer
Silverio, Maria-Theresa
Davis, Maya
O’Donnell, Elizabeth K.
Marinac, Catherine R.
Nadeem, Omar
Bolli, Niccolo https://orcid.org/0000-0002-1018-5139
Yong, Kwee https://orcid.org/0000-0002-6487-276X
Kortüm, K. Martin https://orcid.org/0000-0002-7011-0286
Einsele, Hermann https://orcid.org/0000-0002-7680-0819
Mateos, María-Victoria https://orcid.org/0000-0003-2390-1218
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
San-Miguel, Jesús F. https://orcid.org/0000-0002-9183-4857
Paiva, Bruno https://orcid.org/0000-0003-1977-3815
Kastritis, Efstathios https://orcid.org/0000-0001-8191-5832
Dimopoulos, Meletios A. https://orcid.org/0000-0001-8990-3254
Raab, Marc S. https://orcid.org/0000-0003-4181-6922
Trippa, Lorenzo https://orcid.org/0000-0001-5218-5666
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
- License Information
-
More Information
Article History
Received: 19 May 2025
Accepted: 23 February 2026
First Online: 24 March 2026
Competing interests
: E.K.M. served an advisory board member for Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini/Stemline, Oncopeptides, Pfizer, Sanofi and Takeda; received honoraria from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini/Stemline, Oncopeptides, Pfizer, Sanofi and Takeda; received research funding from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda; and received travel expenses from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini/Stemline, Pfizer, Sanofi and Takeda. D.M.C.d.S. received research funding from Regeneron. J.W. has consulted for Johnson & Johnson, Sanofi, Takeda, Pfizer, Stemline, Oncopeptides and Skyline Dx; received honoraria from Takeda, GlaxoSmithKline and BeiGene; and received research support from Bristol Myers Squibb. L.A. declares grants from the International Myeloma Society for travel and conference expenses. E.K. reports honoraria from Amgen, Janssen, Takeda, Genesis Pharma, Pfizer and GlaxoSmithKline; travel grants from Janssen; and being an advisory board member for Janssen and Prothena. M.A.D. declares honoraria from Amgen, Bristol Myers Squibb, Takeda and Janssen and is an advisory board member for Amgen, Bristol Myers Squibb, Takeda and Janssen. C.R.M. reports research funding from GRAIL. O.N. served on advisory boards for Johnson & Johnson, Bristol Myers Squibb, Sanofi, GPCR Therapeutics, Kite and AstraZeneca and received research funding from Bristol Myers Squibb, Johnson & Johnson and Takeda. N.B. received unrestricted research funding from Janssen; served on advisory boards for Takeda, Pfizer and Johnson & Johnson; and served on speakers bureaus for Johnson & Johnson, Sanofi, Amgen, Oncopeptides, Pfizer and GlaxoSmithKline. M.C.D.V. served on advisory boards for Takeda, Pfizer, Menarini/Stemline, Amgen and Johnson & Johnson and on speakers bureaus for Johnson & Johnson, Sanofi and GlaxoSmithKline. K.M.K. received honoraria and/or research support from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi, Takeda and Stemline. H.E. has consulted for Bristol Myers Squibb, Johnson & Johnson, Amgen, Takeda, Sanofi, GlaxoSmithKline and Novartis; discloses research funding from Bristol Myers Squibb, Johnson & Johnson, Amgen, GlaxoSmithKline and Sanofi; has received honoraria from Bristol Myers Squibb, Johnson & Johnson, Amgen, Takeda, Sanofi, GlaxoSmithKline and Novartis; and received travel support from Bristol Myers Squibb, Johnson & Johnson, Amgen, Takeda, Novartis and Sanofi. J.F.S.-M. reports consultancy fees from AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Haemalogix, Janssen, Karyopharm Therapeutics, Merck Sharp & Dohme, Novartis, Regeneron, Roche, Sanofi, Secura Bio and Takeda. B.P. reports consultancy fees from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Roche, Sanofi and Takeda; research funding from AstraZeneca, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Roche and Sanofi; and honoraria from Adaptive, Amgen, Becton Dickinson Biosciences, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Roche and Sanofi. I.M.G. has consulted for Bristol Myers Squibb, AstraZeneca, Amgen, Curio Science, Sanofi, Johnson & Johnson, Pfizer, Menarini Silicon Biosystems, Aptitude Health, GlaxoSmithKline, AbbVie, Adaptive Biotechnologies, Window Therapeutics and Regeneron. She has received honoraria or speaker fees from Vor Biopharma, Janssen, MJH Life Sciences, Novartis, Takeda, Amgen, Regeneron, Curio Science, Standard Biotools and Physicians’ Education Resource. She is a founder and executive board member of, and holds private equity in, Predicta Biosciences. Her spouse is the chief medical officer of, and holds private equity in, Disc Medicine. The other authors declare no competing interests.
